Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening.
Mühlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U. Mühlberger N, et al. Among authors: siebert u. Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1843. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201843 Free article. No abstract available.
Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Mühlberger N, et al. Among authors: siebert u. Int J Technol Assess Health Care. 2008 Spring;24(2):184-92. doi: 10.1017/S0266462308080264. Int J Technol Assess Health Care. 2008. PMID: 18400122 Review.
Market uptake of new antiviral drugs for the treatment of hepatitis C.
Lettmeier B, Mühlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, Siebert U. Lettmeier B, et al. Among authors: siebert u. J Hepatol. 2008 Oct;49(4):528-36. doi: 10.1016/j.jhep.2008.04.021. Epub 2008 Jun 2. J Hepatol. 2008. PMID: 18682313
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006. Pharmacoeconomics. 2009. PMID: 19485429 Clinical Trial.
697 results